Form 4: Anika Therapeutics CEO Cheryl Blanchard Reports Stock Transactions
SEC Form 4 Filing
Cheryl Blanchard, CEO of Anika Therapeutics, reports the vesting of RSUs and a transfer of shares to a revocable trust.
Summary
- Cheryl Blanchard, the President, CEO, and Director of Anika Therapeutics, reported transactions involving the company's common stock on March 11, 2025.
- These transactions include the vesting of 30,060 Restricted Stock Units (RSUs), the withholding of 12,675 shares to cover tax obligations related to the RSU vesting, and a transfer of 11,742 shares to a revocable trust.
- Following these transactions, Blanchard directly owns 184,340 shares of common stock and indirectly owns 11,742 shares through a revocable trust.
Sentiment
Score: 5
Explanation: The document reflects routine transactions related to executive compensation and personal financial planning, indicating a neutral sentiment.
Industry Context
This Form 4 filing is a routine disclosure related to executive compensation and personal financial management, and doesn't necessarily indicate a strategic shift for Anika Therapeutics.
Stakeholder Impact
- The vesting of RSUs may have a minor dilutive effect on existing shareholders.
- The tax withholding benefits the government.
Key Dates
| Date | Description |
|---|---|
| 2014-12-19 | Date of The Cheryl R. Blanchard Amended and Restated Revocable Trust |
| 2022-03-11 | Date of original RSU grant |
| 2023-03-11 | First vesting date of RSUs |
| 2025-03-11 | Date of RSU vesting, tax withholding, and share transfer |
| 2025-03-13 | Date of Form 4 signature |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.